Myostatin inhibitors have been posed for some time as a way to build muscle and improve mobility in muscular dystrophy patients, but so far this hypothesis has not been confirmed. Pfizer’s announcement today that it is ceasing development of domagrozumab (PF-06252616) in Duchenne muscular dystrophy means the asset will join other failed myostatin inhibitors including Wyeth’s stamulumab and ACE-031 from Acceleron on the discard pile for the indication. The big pharma company said patients taking domagrozumab did not significantly improve their time in the four-stair climb after a year of treatment when compared to patients taking a placebo over the same period in a phase II trial, and secondary endpoints were equally discouraging. This throws the spotlight to Roche’s RG6206, which is due to deliver phase II/III data in 2020.
|Next project up: Myostatin inhibitors for DMD|
|Product||Company||Generic Name||Pharmacological Class||WW Phase (Current)|
|RG6206||Roche||talditercept alfa||Anti-myostatin adnectin||Phase III|
|MCTP300||Myostin Therapeutics||-||Myostatin (GDF-8) antagonist||Pre-clinical|
|EBI-013||Sesen Bio||-||Anti-myostatin (GDF-8) MAb||Pre-clinical|
|OSX200||Ossianix||-||Myostatin (GDF-8) antagonist||Pre-clinical|